FDA Approves Bimekizumab for Three Rheumatologic Conditions ...Middle East

Medscape - News
The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases. Medscape Medical News

Hence then, the article about fda approves bimekizumab for three rheumatologic conditions was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Bimekizumab for Three Rheumatologic Conditions )

Apple Storegoogle play

Last updated :

Also on site :



Latest News